NCT04132505View on ClinicalTrials.gov

Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 22, 2019

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Metastatic Pancreatic AdenocarcinomaStage IV Pancreatic Cancer AJCC v8
Interventions
DRUG

Binimetinib

Given PO

DRUG

Hydroxychloroquine

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER